SCHEMBL2571393

SCHEMBL2571393

O=C(O)c1ccc(NC(=O)c2ccccc2-c2ccccc2)cc1

nearest known ligand 0.78

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CHRNB2 P17787 1/20 0.78
CHRNB4 P30926 1/20 0.78
CHRNA3 P32297 1/20 0.78
CHRNA4 P43681 1/20 0.78
ALDH1A1 P00352 3/20 0.68
GAA P10253 2/20 0.67
POLB P06746 1/20 0.67
CYP3A4 P08684 1/20 0.63
CYP2C9 P11712 1/20 0.63
ALOX12 P18054 1/20 0.63
TP53 P04637 1/20 0.62
PLAU P00749 1/20 0.59
PLAT P00750 1/20 0.59
HTT P42858 4/20 0.58
L3MBTL1 Q9Y468 1/20 0.58
LMNA P02545 1/20 0.58
KDM4E B2RXH2 2/20 0.57
MAPK1 P28482 1/20 0.57
HSD17B10 Q99714 1/20 0.57
FFAR1 O14842 1/20 0.57

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7372972 0.90 CHRNB2 (0.63) CHRNB2CHRNB4CHRNA3CHRNA4ALDH1A1
SCHEMBL1017796 0.88 CHRNB2 (1.00) CHRNB2CHRNB4CHRNA3CHRNA4ALDH1A1
SCHEMBL2571007 0.88 CHRNB2 (0.73) CHRNB2CHRNB4CHRNA3CHRNA4ALDH1A1
SCHEMBL7657583 0.87 PLAU (0.71) CHRNB2CHRNB4CHRNA3CHRNA4ALDH1A1
Hydrochloric Acid SCHEMBL29598779 0.86 CHRNB2 (0.96) CHRNB2CHRNB4CHRNA3CHRNA4ALDH1A1
SCHEMBL3726223 0.86 NPC1 (0.61) CHRNB2CHRNB4CHRNA3CHRNA4ALDH1A1
SCHEMBL16088669 0.86 CHRNB2 (0.58) CHRNB2CHRNB4CHRNA3CHRNA4ALDH1A1
SCHEMBL16127992 0.86 CHRNB2 (0.58) CHRNB2CHRNB4CHRNA3CHRNA4ALDH1A1
SCHEMBL9067133 0.86 ALDH1A1 (0.71) ALDH1A1POLBCYP3A4CYP2C9ALOX12
SCHEMBL4112067 0.85 GAA (0.72) CHRNB2CHRNB4CHRNA3CHRNA4ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 46 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-120025312-A Benzazepine derivatives 大塚制药株式会社 2025-05-23 CN disclosed
US-20250051310-A1 BENZAZEPINE DERIVATIVES OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2025-02-13 US disclosed
EP-4056557-B1 BENZAZEPINE DERIVATIVES USEFUL AS MEDICAMENTS OTSUKA PHARMA CO LTD (JP) 2023-11-22 EP disclosed
US-20230265073-A1 BENZAZEPINE DERIVATIVES OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2023-08-24 US disclosed
US-11673878-B2 Benzazepine derivatives OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2023-06-13 US disclosed
US-20210078976-A1 BENZAZEPINE DERIVATIVES OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2021-03-18 US disclosed
US-10889570-B2 Benzazepine derivatives OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2021-01-12 US disclosed
EP-3645513-A1 BENZAZEPINE DERIVATIVES Otsuka Pharmaceutical Co., Ltd. (JP) 2020-05-06 EP disclosed
WO-2019004421-A1 BENZAZEPINE DERIVATIVES OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2019-01-03 WO disclosed
EP-2078022-B1 SPIRO BENZAZEPINES USED AS VASOPRESSIN ANTAGONISTS JANSSEN PHARMACEUTICA NV (BE) 2011-11-09 EP disclosed
EP-0804420-A1 TRICYCLIC BENZAZEPINE VASOPRESSIN ANTAGONISTS American Cyanamid Company (US) 1997-11-05 EP disclosed
EP-0804438-A1 TRICYCLIC BENZAZEPINE VASOPRESSIN ANTAGONISTS American Cyanamid Company (US) 1997-11-05 EP disclosed
US-5612334-A Tricyclic benzazepine vasopressin antagonists AMERICAN CYANAMID COMPANY (US) 1997-03-18 US disclosed
US-5610156-A USED IN TREATING DISEASES CHARACTERIZED BY EXCESS RENAL REABSORPTION OF WATER AMERICAN CYANAMID COMPANY (US) 1997-03-11 US disclosed
WO-1996022295-A9 TRICYCLIC BENZAZEPINE VASOPRESSIN ANTAGONISTS 1996-11-14 WO disclosed
WO-1996022293-A1 TRICYCLIC BENZAZEPINE VASOPRESSIN ANTAGONISTS AMERICAN CYANAMID COMPANY (US) 1996-07-25 WO disclosed
WO-1996022282-A1 TRICYCLIC BENZAZEPINE VASOPRESSIN ANTAGONISTS AMERICAN CYANAMID COMPANY (US) 1996-07-25 WO disclosed
WO-1996022295-A1 TRICYCLIC BENZAZEPINE VASOPRESSIN ANTAGONISTS AMERICAN CYANAMID COMPANY (US) 1996-07-25 WO disclosed
US-5536718-A Tricyclic benzazepine vasopressin antagonists AMERICAN CYANAMID COMPANY (US) 1996-07-16 US disclosed
US-5532235-A TO TREAT EXCESS RENAL REABSORPTION AMERICAN CYANAMID COMPANY (US) 1996-07-02 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20210078976-A1 BENZAZEPINE DERIVATIVES AVPR2, AVPR1A, AVPR1B CHRNB2 1161/4885CHRNB4 1377/4885CHRNA3 1036/4885
US-20230265073-A1 BENZAZEPINE DERIVATIVES AVPR2, AVPR1A, AVPR1B CHRNB2 1161/4885CHRNB4 1377/4885CHRNA3 1036/4885
US-11673878-B2 Benzazepine derivatives AVPR2, AVPR1A, AVPR1B CHRNB2 1161/4885CHRNB4 1377/4885CHRNA3 1036/4885
US-20250051310-A1 BENZAZEPINE DERIVATIVES AVPR2, AVPR1A, AVPR1B CHRNB2 1109/4885CHRNB4 1349/4885CHRNA3 1025/4885
US-10889570-B2 Benzazepine derivatives AVPR2, AVPR1A, AVPR1B CHRNB2 1161/4885CHRNB4 1377/4885CHRNA3 1036/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.